🏛️ Verified NIH Record • Updated 2026-04-29
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (NCT05400109)
A Phase 1/1b Multicenter, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With B Cell Non-Hodgkin Lymphomas
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: David Wald
🩺 Plain-English Summary (8th-Grade Level)
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Who can join: Review the eligibility criteria below.
Location: University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Hodgkin Lymphoma
- Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) — Duarte, California
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma — Tucson, Arizona
- TmCD19-IL18 in CD19+ Cancers — Philadelphia, Pennsylvania
- Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma — Cincinnati, Ohio
- Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies — Cleveland, Ohio
Explore by condition: All Non Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.